Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials has been accepted for presentation at the (Sociedad Latinoamericana de Endocrinología Pediátrica), or SLEP 2024, to be held September 11-14, 2024 in Santiago, Chile.
Abstract Presentation: Friday, September 13th – E-poster Session 2 – 1:15-2:30PM Local Time
- Abstract entitled, LUM-201 Restores Growth Hormone Secretion and Promotes Growth in Moderate Pediatric Growth Hormone Deficiency (PGHD): Phase 2 Topline Results from OraGrowtH210 and OraGrowtH212 Trials (Rossana Román, MD, et al)
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit .
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
Source: Lumos Pharma, Inc.
